Table 5.
OS and TNTD among nab-paclitaxel initiators by line of therapy and treatment regimena,b
| Variable | Total no. | OS | TNTD | ||||
|---|---|---|---|---|---|---|---|
| Events | Median, mo | 95 % CI | Events | Median, mo | 95 % CI | ||
| Overall | 664 | 305 | 17.4 | (16.1–19.0) | 491 | 6.1 | (5.6–6.7) |
| Monotherapy | 405 | 184 | 16.8 | (14.5–18.5) | 293 | 5.8 | (5.0–6.7) |
| Combination therapy | 259 | 121 | 18.7 | (15.9–24.0) | 198 | 6.5 | (5.8–7.8) |
| First line | 172 | 68 | 22.7 | (18.6–34.3) | 127 | 7.1 | (6.2–9.0) |
| Monotherapy | 109 | 37 | 20.8 | (16.5–39.2) | 76 | 6.7 | (5.0–7.4) |
| Combination therapy | 63 | 31 | 23.0 | (18.7–37.3) | 51 | 8.5 | (6.5–13.1) |
| Second line | 211 | 99 | 17.4 | (14.1–22.3) | 151 | 6.6 | (5.3–8.1) |
| Monotherapy | 129 | 67 | 15.6 | (12.8–21.4) | 97 | 5.8 | (4.7–7.9) |
| Combination therapyc | 82 | 32 | >18.7 | – | 54 | 7.3 | (5.1–9.7) |
| Third or later line | 281 | 138 | 15.1 | (12.7–16.9) | 213 | 5.3 | (4.6–6.0) |
| Monotherapy | 167 | 80 | 15.6 | (11.6–17.8) | 120 | 5.3 | (4.2–6.1) |
| Combination therapy | 114 | 58 | 14.3 | (11.9–17.4) | 93 | 5.5 | (4.6–6.4) |
OS overall survival, TNTD time to next therapy or death
aData are from the Optum Research Database, January 1, 2005 to September 30, 2012
bFollow-up time was calculated from index date until disenrollment from the health plan, death (or treatment discontinuation), or the end of the study period (September 30, 2012)
cThe 95 % CI of median survival time is missing because more than half of the patients survived during the study period